Edition:
United States

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

23.21EUR
6:50am EDT
Change (% chg)

€-0.32 (-1.36%)
Prev Close
€23.53
Open
€23.54
Day's High
€23.54
Day's Low
€23.04
Volume
6,997
Avg. Vol
4,499
52-wk High
€40.06
52-wk Low
€23.04

Chart for

About

Carmat SAS is a France-based Company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The Company formed a network of partnerships with hospitals and various scientific... (more)

Overall

Beta: 0.80
Market Cap(Mil.): €139.46
Shares Outstanding(Mil.): 5.93
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.61 15.95
EPS (TTM): -- -- --
ROI: -- 13.28 15.19
ROE: -- 16.11 13.87

French implant maker Carmat pins hopes on low energy heart

PARIS Artificial heart maker Carmat is hoping a more energy-efficient implant and the appointment of a production chief can help it overcome recent failures at the French firm.

Jul 05 2017

Carmat buoyed by approval to resume artificial heart trial

Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume a heart implant trial, sending the company's shares more than one fifth higher on Wednesday.

May 03 2017

UPDATE 2-Carmat buoyed by approval to resume artificial heart trial

May 3 Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume a heart implant trial, sending the company's shares more than one fifth higher on Wednesday.

May 03 2017

Carmat gets approval to resume artificial heart implants trial

May 2 Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume heart implant trials, the company said on Tuesday.

May 02 2017

Earnings vs. Estimates